NASDAQ:VXRT Vaxart Q1 2024 Earnings Report $0.40 +0.04 (+11.31%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.40 +0.00 (+0.82%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Vaxart EPS ResultsActual EPS-$0.14Consensus EPS -$0.16Beat/MissBeat by +$0.02One Year Ago EPSN/AVaxart Revenue ResultsActual Revenue$2.18 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVaxart Announcement DetailsQuarterQ1 2024Date5/13/2024TimeN/AConference Call DateMonday, May 13, 2024Conference Call Time4:30PM ETUpcoming EarningsVaxart's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Vaxart Q1 2024 Earnings Call TranscriptProvided by QuartrMay 13, 2024 ShareLink copied to clipboard.There are 10 speakers on the call. Operator00:00:00Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel. Speaker 100:00:30Good afternoon, and welcome to today's call. Joining us from Vaxart are Stephen Lowe, Chief Executive Officer Doctor. Sean Tucker, Founder and Chief Scientific Officer Doctor. James Cummings, Chief Medical Officer and Philip Lee, Chief Financial Officer. Before we begin, I would like to remind everyone that during this conference call, Daxart may make forward looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. Speaker 100:01:17Actual results could materially differ from those discussed in these forward looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10 ks and also on other periodic reports filed with the SEC. Baxart undertakes no obligation to update any forward looking statements after the date of this call. I'll now turn the call over to Stephen Lowe. Steve? Speaker 200:01:59Thanks, Ed, and thanks to all of you for joining us today. On today's call, I'll provide a brief summary of my background, discuss our recent accomplishments and share details of our exciting value proposition. I'll then turn the call over to James and Phil to review our recent progress, which includes positive data from our bivalent norovirus vaccine candidate in lactating mothers, upcoming milestones and a financial update. Since this is my first quarterly results call as Vaxart's CEO, I'd like to begin with a brief introduction. I've spent most of my 25 plus year career in the healthcare, biotech and pharmaceutical sectors, including more than 12 years as a C level executive at publicly traded biotech companies. Speaker 200:02:50Throughout that time, I have led companies through all phases of drug development from preclinical to launching and commercializing products. In my previous roles, I have worked firsthand in developing clinical programs and executing commercial strategies, experience that will be crucial as we advance Vaxart's pipeline. I enjoy working in biotech because it provides the opportunity to find the right health care solutions to society's most pressing unsolved problems. This is what led me to Vaxart, where I believe we have a promising science and a passionate team of scientific experts driven to bring transformative solutions to benefit public health globally. I am excited to lead Vaxart as we bring our pipeline of cutting edge vaccine candidates to improve outcomes in public health. Speaker 200:03:48A major emphasis of mine will be on execution so that we can deliver on Vaxart's promise more quickly in order to solve major public health issues while generating value for our shareholders. And now a couple of comments on our pipeline progress. First, we are very pleased with the recent positive results from the Phase 1 clinical trial evaluating our oral pill bivalent norovirus vaccine candidate in lactating mothers. The top line analysis from this study showed that our vaccine could significantly increase antibodies against norovirus in breast milk. This is an important first signal for the potential of our vaccine to protect against or reduce disease severity of norovirus in the youngest and most vulnerable population as this virus carries a tremendous economic burden in the United States and other developed countries around the world. Speaker 200:04:52The next step for our norovirus program will be a meeting with the FDA in mid-twenty 24 to review our clinical findings to date, which include our dose ranging Phase 2 study of our bivalent norovirus vaccine candidate and our Phase 2 challenge study of the G11 component of our bivalent norovirus vaccine candidate. We anticipate this meeting will assist us in determining the regulatory pathway and clinical next steps. 2nd, we expect to initiate our COVID-nineteen Phase 2b trial possibly as early as this quarter once we are able to secure additional funding and gain regulatory alignment. We have been honored to receive an initial contract from BARDA and look forward to working with them on Project NextGen as we continue preparations for this trial. This Phase 2b study will evaluate our oral pill XBB COVID-nineteen vaccine candidate against an improved mRNA comparator. Speaker 200:06:03We agree with the federal government that better vaccines are needed and believe these next generation vaccines will include those that harness the power of mucosal immunity like our innovative candidates. We look forward to providing an update on funding and our timing as events warrant. We are proud of the growing body of data that reinforces our confidence in our differentiated technology and we continue to improve this technology. Recent preclinical data suggests our COVID-nineteen XBB construct has produced a more robust immunogenic response compared with our previous constructs. With these results, we are exploring whether certain changes we implemented in our XBB vaccine candidate will also be beneficial for other indications in our pipeline. Speaker 200:06:56We believe Vaxart is in an excellent position to seize determined to and we are determined to press on toward our goal of bringing these solutions to the populations that need them, both in the United States and globally. I'll now turn the call over to James to review the recent progress of our norovirus and COVID-nineteen programs. Speaker 300:07:29Thanks, Steve. We're encouraged by our progress in both our norovirus and COVID-nineteen programs. 1st, on norovirus. Late last month, we announced positive top line data from our Phase 1 clinical trial evaluating the ability of our norovirus vaccine candidate to induce antibodies in lactating mothers' breast milk. Recall that this study was partially supported by the Bill and Melinda Gates Foundation. Speaker 300:07:59We found in our initial analyses that antibodies to norovirus rose on average fourfold for the G11 virus strain and 6 fold for the G24 virus strain in the breast milk of lactating mothers who received the Vaxart vaccine candidate in the high dose group. Importantly, there were no vaccine related serious adverse events and no dose limiting pharmacotoxicity. These key findings may offer hope for mothers to protect their children against or reduce the effect of this highly contagious virus. While mucosal immunization of the youngest of children is challenging due to the nature of their developing immune system, Our creative approach in the passive transfer of antibodies from mothers to infants could potentially improve infection resistance in infants. Globally, norovirus is a very serious illness with an economic burden estimated at more than 60 $1,000,000,000 annually. Speaker 300:09:06It is particularly prevalent among the youngest age group, children under 8 years of age, as norovirus carries a tremendous rate of outbreak incidents compared with other infectious diseases. In the developing world, it carries a much higher mortality rate than in developing nations, especially in countries that already have a rotavirus vaccine program. Norovirus causes an estimated 50,000 child deaths every year, mostly in developing countries. As a reminder, this was a Phase 1, multicenter, randomized, double blind, placebo controlled, dose ranging study designed to evaluate the safety, tolerability and immunogenicity of orally administered bivalent G11, G24 norovirus vaccine in healthy, lactating females of at least 18 years of age. The study enrolled 76 subjects in 5 sites in South Africa. Speaker 300:10:12Subjects were randomized into high or medium dose vaccine or placebo groups. Safety data from this study remains blinded and will become available 12 months after enrollment. We are conducting additional analyses of the study data, and we expect to report more complete results, including other immunogenicity measures in a future scientific manuscript. Looking ahead, as Steve mentioned, we are targeting a mid-twenty 24 meeting with the FDA to discuss our data on potential correlates of protection as well as potential future clinical studies such as a Phase 2b dose confirmation study and if required, a G24 challenge study. We are hopeful that supporting safety data from a Phase 2b study could result in the end of Phase 2 meeting with the FDA that would focus on the scope and design of a Phase 3 pivotal efficacy study for our norovirus vaccine in adults over 18 years of age. Speaker 300:11:18Turning now to our COVID-nineteen program. We continue to make progress in preparing for a 10,000 subject Phase 2b clinical trial evaluating our oral pill XBB COVID-nineteen vaccine candidate against an improved mRNA vaccine comparator. You may recall the preparations for the study were supported by a contract from BARDA and are part of the federal government's Project NextGen effort to enhance the nation's pandemic preparedness and better confront the continuing challenge of COVID-nineteen. We have substantially completed the preparations of our manufacturing processes in advance of the launch of this trial. We're working to secure additional funding and regulatory alignment, and if successful, we currently anticipate initiating this Phase 2b trial as early as the Q2. Speaker 300:12:16As background, this is a Phase 2b, double blind, multicenter, randomized, comparator controlled clinical trial to determine the relative efficacy, safety and immunogenicity of Vaxart's investigational oral SARS CoV-two XBB vaccine tablet against a currently approved mRNA needle injected booster vaccine in adults previously immunized against COVID-nineteen infection. I'll now hand the call over to Phil Lee, our Chief Financial Officer, for a brief discussion of our financials. Phil? Speaker 400:12:56Thank you, James. The details of our financial results for the Q1 of 2024 are summarized in today's press release. Revenue for the Q1 of 2024 was $2,200,000 compared to $700,000 in the Q1 of 2023. Revenue in the Q1 of 2024 was primarily from revenue recognized or work performed under Vaxart's contract from BARDA and non cash royalty revenue from sales of Innovir in Japan. Baxter ended the Q1 with cash, cash equivalents and investments of $36,700,000 While we did not receive any cash payments from BARDA during the Q1, we have received approximately $1,600,000 subsequent to the end of the quarter. Speaker 400:13:49We are in the process of executing on the remaining deliverables and submitting for the remaining 7 point $67,000,000 portion of our current BARDA contract and we'll provide an update when we report our Q2 financial results. Based on our current plan, Vaxart anticipates current cash runway into late Q4 of 2024. Thanks everyone for your time today. We will now open the call for your questions. Operator00:14:19Thank you. And ladies and gentlemen, at this time, we'll conduct our question and answer session. And our first question comes from Mayank Mamtani with B. Riley Securities. Please state your questions. Speaker 500:15:09Hey, guys. This is Madison on for Mayank. Thank you for taking our question. I wanted to ask, so maybe could you speak to what you need to demonstrate to procure this additional funding in order to initiate the Phase 2b BARDA? And maybe if you could speak to your confidence level on where you're at regarding obtaining those funds that are needed? Speaker 200:15:43Yes. Hi, good afternoon. Thanks for the question. So I'll cover a few things and then I'll turn it over to James on the specifics. In terms of confidence level, right, so the original award of the $9,270,000 was to fund the preparation for the 10,000 subject study. Speaker 200:16:02And as both James and I have outlined, we've made progress there. And I think you can even see in the financial results, we've been reimbursed for some of that work. So that is why we continue to say that we're prepared to start the trial as early as this quarter. But let me also turn it over to James. Speaker 600:16:25Thanks, Steve. In terms of the preparation for the study, I think the team has done an excellent job in putting together the pieces for evaluation of the XBB construct against an improved mRNA comparative vaccine. This is a big study, it's 10,000 people, right? And so to get all those food groups set up, it takes the team and we've got a good one. In terms of where we're at, we'll report back when we have those details for you. Speaker 600:16:57But we've been in close communication with BARDA on the preparations, and we plan to provide an update on funding and on our timing as applicable. Thanks. Speaker 500:17:11I see. Thanks, guys. Operator00:17:15Thank you. And our next question comes from Charles Duncan with Cantor Fitzgerald. Please state your question. Speaker 700:17:24Hi, team. This is Asiya on for Charles. Thank you for taking our questions. So we also have a question regarding the Phase 2b study for the COVID-nineteen vaccine. Can you talk about possible specific endpoints and criteria that will be used to evaluate its efficacy and safety against the mRNA vaccine comparator? Speaker 700:17:50And can you also elaborate on what enrollment for this study would look like such as where you might enroll patients from and are there any other challenges you might anticipate? Speaker 200:18:02Sure. I'll turn that over to James since he has the details on that. Speaker 600:18:08Sure. So as far as where we're actually executing the clinical trial, it's planned to be executed here in the United States. And in terms of enrollment, it would be healthy individuals and individuals at risk above the age of 18. It's important that we test this vaccine against the comparator mRNA vaccine in a population that's likely to do the most good. So we're moving along those lines. Speaker 600:18:38What was the second part of your question, ASEA? Speaker 700:18:43So it was about possible endpoints and criteria that you will be using for the study? Speaker 600:18:50Yes. So the endpoints are safety always, right? And we're very fortunate in that our platform across every article in our pipeline portfolio has been very well received, very safe and well tolerated. We'll also be looking at efficacy, both for symptomatic COVID-nineteen infection compared to the comparator vaccine. And we'll be looking at the immunological readouts and mucosal readouts of that vaccine. Speaker 700:19:23Okay. Thank you so much. That makes a lot of sense. Speaker 400:19:27Thank you. Operator00:19:31And our next question comes from Roger Song with Jefferies. Please state your question. Speaker 800:19:37Hey, good afternoon. This is Liang Chen on for Roger. Thank you for taking our questions. I guess from us, so understand that you have met with the FDA yet, but regarding the potential Phase 2 challenge study, So what would be some considerations around whether there would be such a study or no? And also I have a question about the potential immunology correlates. Speaker 800:20:08So could you remind us if you are still continuing on data analysis and are there any updates or plans on the immunogenicity correlates? Thank you. Speaker 200:20:24Sure. Yes. I'll turn it over to James shortly. My high level is, obviously, what we've stated in terms of our meeting with the FDA is we're still targeting middle of this year. And James can cover a bit more about that. Speaker 600:20:43Thanks, Steve. So as we mentioned, we'll be planning to we'll be meeting with the FDA in mid-twenty 24. And we'll review our clinical findings to date. That includes data on potential correlates of protection. We anticipate this meeting will assist us in determining the proper regulatory pathway and clinical next steps. Speaker 600:21:06And as I mentioned in my brief, some of these steps could include a Phase 2b dose confirmation study and if required, a G24 challenge study. But I'd like to get input from the agency. We'll determine the timing of any future norovirus studies after our discussions with the FDA. Speaker 800:21:31Got it. That makes sense. So, also regarding the Phase 1 lactating mothers data, I know the detailed data will be published in future. Would there be any data around measurements in the infants? Speaker 200:21:51James or Sean, either one of you want to take that? Speaker 600:21:55Sure. So the data we have to date, Leon, is some of the top line data and we continue to perform analyses. Some of those analyses will look at fecal, the amount of material in the infant species. But that's again down the road a bit. Speaker 800:22:22Got it. Thank you. That's all from us. Thanks again. Operator00:22:27Thank you. I would now like to turn the call back to Ed Berg for further questions. Speaker 100:22:35Okay. Thank you. Have additional questions that came in from investors. So I will start with our Phase 2b COVID study. And this is for James. Speaker 100:22:48Do you have enough manufacturing capacity to produce your COVID vaccine for the Phase 2b trial? Speaker 600:22:56Sure. Thanks for the question. Yes, beef have sufficient material that's already been produced. Speaker 100:23:05Thanks. The other question for you, James, on COVID the COVID trial is how does the fall COVID-nineteen booster season affect Vaxart's ability to procure mRNA vaccines for use in the control arm? Speaker 600:23:28Thanks, Ed. So this study is actually a comparator of homologous vaccines, 2 vaccines that are geared towards the same strain of the virus. We've already procured an XBV mRNA vaccine that is the comparative construct that we need for this trial. Speaker 100:23:52Thanks, James. On the 108 study, this is for Sean. In your recent press release announcing the Lactating Mothers study data, you mentioned antibody increase figures. How do these compare to the other published data? Speaker 900:24:12Yes, that's a great question. Well, there haven't been as many studies have done where the women postpartum have been vaccinated. Most studies in mothers have done in 3rd trimester, not after the infant is born. Moreover, there haven't really been that many actually been no doravirus vaccine trials in lactating mothers. Having said that, from the few studies that we will define on vaccination in postpartum mothers, we believe our results compare quite favorably. Speaker 900:24:41We're getting a similar response or better than what's been described. Speaker 100:24:49Thanks. Sean, back to the this is one for Sean, but back to COVID-nineteen and the Phase 2b trial. The question is what differentiates Vaxart's technology from the other next gen COVID vaccines that received contracts from BARDA? Speaker 900:25:07Well, first off, we're the only oral pill vaccine that's currently been contracted in the project next gen recipients. The benefit that we see is that it's just more convenient for administering our vaccine by injection or better than a nasal spray. The other advantage we have of course is that as James mentioned before is we actually have our own manufacturing facilities and they've been able to make vaccine quickly and it's competitive advantage for us because of that. Speaker 100:25:41Thanks. This one is also for Sean. And I think Steve, you might want to step in and make some comments. The question is how do you intend to educate the medical community and consumers on your COVID and norovirus oral vaccine benefits in order to rapidly drive adoption in the U. S, the U. Speaker 100:26:01K. And broadly, particularly given what has been learned about the shortcomings of existing vaccines and overall vaccine hesitancy. And of course, I will as the lawyer, I will state that we don't we're not going to be promoting our vaccines until they're approved. But there are other methods of communicating information. So Sean, with that, feel free to Speaker 800:26:28add. Sure. Speaker 900:26:29Well, we think our tablet vaccine will do well from the standpoint of overcoming vaccine hesitancy. In fact, we did do some previous polling data conducted in 2021 2022 and the latest suggests that 8 out of 10 recipients would prefer a pill to a shot or a nasal spray. So further, we have gone to various medical conferences and conferences and we have seen lots of positive feedback about our approach and we think the excitement is indicative of the understanding in the medical community that there may be some pent up demand for a new technology that's easier to use. Speaker 400:27:10Steve? Speaker 200:27:12Yes. Thanks, Sean. Sean is being modest. He gets invited to a lot of conferences to speak and I think any sort of scientific exchange like that is important. And I think as we continue releasing more data, having that opportunity to do so is important to us. Speaker 200:27:31As Ed mentioned, we're not FDA approved as of yet. So we'll stick to the regular medical scientific exchanges to make sure that what we have in our data is out there for everyone to absorb. Speaker 100:27:49Thank you, Steve. Another question directed to you. You mentioned in your prepared remarks having better execution. How do you think that can be accomplished? Speaker 200:28:02Yes. Thanks for the question. Well, I think first and foremost, we as a company want to make sure that we have our priorities set. And I'm delighted to see that we have, you've seen already or heard today, we've talked about making sure that we execute on the agreement with BARDA to prepare for this upcoming 10,000 subject trial. And it's already been demonstrated with the fact that as James mentioned, we have made great progress on the manufacturing front. Speaker 200:28:35We prepared and are preparing for the trial to the extent that you've heard more details about it. And so to me that is continued to execute. We want to balance that with making sure that we're very rigorous with everything that we're doing, but also understanding that we want to help the public out there. So anything we can do to balance that with good speed is also important. And that's certainly how I look at having better execution. Speaker 100:29:11Thanks. Last question for Steve. It's been nearly 2 months since you arrived as CEO. What have you learned in that time? Speaker 200:29:22Great. Thanks for that question. First and foremost, let me just say I'm delighted to be here. What I have found and learned is that this is what we have here at Vaxart is very promising science and one of the main reasons why I wanted to come here. And secondly, now that I've been here for 2 months, getting a chance to work side by side with the employees, our scientists, everybody, I can say that we are very passionate about our work and our mission. Speaker 200:29:52And if you combine the promising science with dedicated employees here at Backstart, we are very focused on wanting to advance our vaccine candidates forward and get it out there as soon as we can with the approvals that we need and with the trials that we need to execute and conduct. But we are very focused on execution and also delivering value to our stakeholders. Speaker 100:30:24Thanks, Steve. Thank you everyone for tuning in. I will turn it back over to our operator to close out the call. Operator00:30:35Thank you. This concludes conference. You may disconnect your lines at this time and have a wonderful day. We thank you for your participation today.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallVaxart Q1 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vaxart Earnings HeadlinesVaxartto Present at World Vaccine Congress Washington 2025 on April 23April 16, 2025 | globenewswire.comVaxart price target lowered to $2 from $2.50 at B. RileyMarch 27, 2025 | markets.businessinsider.comSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.April 26, 2025 | Stansberry Research (Ad)Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 27, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call TranscriptMarch 24, 2025 | insidermonkey.comVaxart, Inc. (VXRT) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comSee More Vaxart Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vaxart? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vaxart and other key companies, straight to your email. Email Address About VaxartVaxart (NASDAQ:VXRT), a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.View Vaxart ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 10 speakers on the call. Operator00:00:00Greetings, and welcome to the Vaxart Business Update and First Quarter 2024 Financial Results Conference Call. As a reminder, this conference is being recorded. I would now like to turn the webcast over to your host, Ed Berg, Senior Vice President and General Counsel. Speaker 100:00:30Good afternoon, and welcome to today's call. Joining us from Vaxart are Stephen Lowe, Chief Executive Officer Doctor. Sean Tucker, Founder and Chief Scientific Officer Doctor. James Cummings, Chief Medical Officer and Philip Lee, Chief Financial Officer. Before we begin, I would like to remind everyone that during this conference call, Daxart may make forward looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. Speaker 100:01:17Actual results could materially differ from those discussed in these forward looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10 ks and also on other periodic reports filed with the SEC. Baxart undertakes no obligation to update any forward looking statements after the date of this call. I'll now turn the call over to Stephen Lowe. Steve? Speaker 200:01:59Thanks, Ed, and thanks to all of you for joining us today. On today's call, I'll provide a brief summary of my background, discuss our recent accomplishments and share details of our exciting value proposition. I'll then turn the call over to James and Phil to review our recent progress, which includes positive data from our bivalent norovirus vaccine candidate in lactating mothers, upcoming milestones and a financial update. Since this is my first quarterly results call as Vaxart's CEO, I'd like to begin with a brief introduction. I've spent most of my 25 plus year career in the healthcare, biotech and pharmaceutical sectors, including more than 12 years as a C level executive at publicly traded biotech companies. Speaker 200:02:50Throughout that time, I have led companies through all phases of drug development from preclinical to launching and commercializing products. In my previous roles, I have worked firsthand in developing clinical programs and executing commercial strategies, experience that will be crucial as we advance Vaxart's pipeline. I enjoy working in biotech because it provides the opportunity to find the right health care solutions to society's most pressing unsolved problems. This is what led me to Vaxart, where I believe we have a promising science and a passionate team of scientific experts driven to bring transformative solutions to benefit public health globally. I am excited to lead Vaxart as we bring our pipeline of cutting edge vaccine candidates to improve outcomes in public health. Speaker 200:03:48A major emphasis of mine will be on execution so that we can deliver on Vaxart's promise more quickly in order to solve major public health issues while generating value for our shareholders. And now a couple of comments on our pipeline progress. First, we are very pleased with the recent positive results from the Phase 1 clinical trial evaluating our oral pill bivalent norovirus vaccine candidate in lactating mothers. The top line analysis from this study showed that our vaccine could significantly increase antibodies against norovirus in breast milk. This is an important first signal for the potential of our vaccine to protect against or reduce disease severity of norovirus in the youngest and most vulnerable population as this virus carries a tremendous economic burden in the United States and other developed countries around the world. Speaker 200:04:52The next step for our norovirus program will be a meeting with the FDA in mid-twenty 24 to review our clinical findings to date, which include our dose ranging Phase 2 study of our bivalent norovirus vaccine candidate and our Phase 2 challenge study of the G11 component of our bivalent norovirus vaccine candidate. We anticipate this meeting will assist us in determining the regulatory pathway and clinical next steps. 2nd, we expect to initiate our COVID-nineteen Phase 2b trial possibly as early as this quarter once we are able to secure additional funding and gain regulatory alignment. We have been honored to receive an initial contract from BARDA and look forward to working with them on Project NextGen as we continue preparations for this trial. This Phase 2b study will evaluate our oral pill XBB COVID-nineteen vaccine candidate against an improved mRNA comparator. Speaker 200:06:03We agree with the federal government that better vaccines are needed and believe these next generation vaccines will include those that harness the power of mucosal immunity like our innovative candidates. We look forward to providing an update on funding and our timing as events warrant. We are proud of the growing body of data that reinforces our confidence in our differentiated technology and we continue to improve this technology. Recent preclinical data suggests our COVID-nineteen XBB construct has produced a more robust immunogenic response compared with our previous constructs. With these results, we are exploring whether certain changes we implemented in our XBB vaccine candidate will also be beneficial for other indications in our pipeline. Speaker 200:06:56We believe Vaxart is in an excellent position to seize determined to and we are determined to press on toward our goal of bringing these solutions to the populations that need them, both in the United States and globally. I'll now turn the call over to James to review the recent progress of our norovirus and COVID-nineteen programs. Speaker 300:07:29Thanks, Steve. We're encouraged by our progress in both our norovirus and COVID-nineteen programs. 1st, on norovirus. Late last month, we announced positive top line data from our Phase 1 clinical trial evaluating the ability of our norovirus vaccine candidate to induce antibodies in lactating mothers' breast milk. Recall that this study was partially supported by the Bill and Melinda Gates Foundation. Speaker 300:07:59We found in our initial analyses that antibodies to norovirus rose on average fourfold for the G11 virus strain and 6 fold for the G24 virus strain in the breast milk of lactating mothers who received the Vaxart vaccine candidate in the high dose group. Importantly, there were no vaccine related serious adverse events and no dose limiting pharmacotoxicity. These key findings may offer hope for mothers to protect their children against or reduce the effect of this highly contagious virus. While mucosal immunization of the youngest of children is challenging due to the nature of their developing immune system, Our creative approach in the passive transfer of antibodies from mothers to infants could potentially improve infection resistance in infants. Globally, norovirus is a very serious illness with an economic burden estimated at more than 60 $1,000,000,000 annually. Speaker 300:09:06It is particularly prevalent among the youngest age group, children under 8 years of age, as norovirus carries a tremendous rate of outbreak incidents compared with other infectious diseases. In the developing world, it carries a much higher mortality rate than in developing nations, especially in countries that already have a rotavirus vaccine program. Norovirus causes an estimated 50,000 child deaths every year, mostly in developing countries. As a reminder, this was a Phase 1, multicenter, randomized, double blind, placebo controlled, dose ranging study designed to evaluate the safety, tolerability and immunogenicity of orally administered bivalent G11, G24 norovirus vaccine in healthy, lactating females of at least 18 years of age. The study enrolled 76 subjects in 5 sites in South Africa. Speaker 300:10:12Subjects were randomized into high or medium dose vaccine or placebo groups. Safety data from this study remains blinded and will become available 12 months after enrollment. We are conducting additional analyses of the study data, and we expect to report more complete results, including other immunogenicity measures in a future scientific manuscript. Looking ahead, as Steve mentioned, we are targeting a mid-twenty 24 meeting with the FDA to discuss our data on potential correlates of protection as well as potential future clinical studies such as a Phase 2b dose confirmation study and if required, a G24 challenge study. We are hopeful that supporting safety data from a Phase 2b study could result in the end of Phase 2 meeting with the FDA that would focus on the scope and design of a Phase 3 pivotal efficacy study for our norovirus vaccine in adults over 18 years of age. Speaker 300:11:18Turning now to our COVID-nineteen program. We continue to make progress in preparing for a 10,000 subject Phase 2b clinical trial evaluating our oral pill XBB COVID-nineteen vaccine candidate against an improved mRNA vaccine comparator. You may recall the preparations for the study were supported by a contract from BARDA and are part of the federal government's Project NextGen effort to enhance the nation's pandemic preparedness and better confront the continuing challenge of COVID-nineteen. We have substantially completed the preparations of our manufacturing processes in advance of the launch of this trial. We're working to secure additional funding and regulatory alignment, and if successful, we currently anticipate initiating this Phase 2b trial as early as the Q2. Speaker 300:12:16As background, this is a Phase 2b, double blind, multicenter, randomized, comparator controlled clinical trial to determine the relative efficacy, safety and immunogenicity of Vaxart's investigational oral SARS CoV-two XBB vaccine tablet against a currently approved mRNA needle injected booster vaccine in adults previously immunized against COVID-nineteen infection. I'll now hand the call over to Phil Lee, our Chief Financial Officer, for a brief discussion of our financials. Phil? Speaker 400:12:56Thank you, James. The details of our financial results for the Q1 of 2024 are summarized in today's press release. Revenue for the Q1 of 2024 was $2,200,000 compared to $700,000 in the Q1 of 2023. Revenue in the Q1 of 2024 was primarily from revenue recognized or work performed under Vaxart's contract from BARDA and non cash royalty revenue from sales of Innovir in Japan. Baxter ended the Q1 with cash, cash equivalents and investments of $36,700,000 While we did not receive any cash payments from BARDA during the Q1, we have received approximately $1,600,000 subsequent to the end of the quarter. Speaker 400:13:49We are in the process of executing on the remaining deliverables and submitting for the remaining 7 point $67,000,000 portion of our current BARDA contract and we'll provide an update when we report our Q2 financial results. Based on our current plan, Vaxart anticipates current cash runway into late Q4 of 2024. Thanks everyone for your time today. We will now open the call for your questions. Operator00:14:19Thank you. And ladies and gentlemen, at this time, we'll conduct our question and answer session. And our first question comes from Mayank Mamtani with B. Riley Securities. Please state your questions. Speaker 500:15:09Hey, guys. This is Madison on for Mayank. Thank you for taking our question. I wanted to ask, so maybe could you speak to what you need to demonstrate to procure this additional funding in order to initiate the Phase 2b BARDA? And maybe if you could speak to your confidence level on where you're at regarding obtaining those funds that are needed? Speaker 200:15:43Yes. Hi, good afternoon. Thanks for the question. So I'll cover a few things and then I'll turn it over to James on the specifics. In terms of confidence level, right, so the original award of the $9,270,000 was to fund the preparation for the 10,000 subject study. Speaker 200:16:02And as both James and I have outlined, we've made progress there. And I think you can even see in the financial results, we've been reimbursed for some of that work. So that is why we continue to say that we're prepared to start the trial as early as this quarter. But let me also turn it over to James. Speaker 600:16:25Thanks, Steve. In terms of the preparation for the study, I think the team has done an excellent job in putting together the pieces for evaluation of the XBB construct against an improved mRNA comparative vaccine. This is a big study, it's 10,000 people, right? And so to get all those food groups set up, it takes the team and we've got a good one. In terms of where we're at, we'll report back when we have those details for you. Speaker 600:16:57But we've been in close communication with BARDA on the preparations, and we plan to provide an update on funding and on our timing as applicable. Thanks. Speaker 500:17:11I see. Thanks, guys. Operator00:17:15Thank you. And our next question comes from Charles Duncan with Cantor Fitzgerald. Please state your question. Speaker 700:17:24Hi, team. This is Asiya on for Charles. Thank you for taking our questions. So we also have a question regarding the Phase 2b study for the COVID-nineteen vaccine. Can you talk about possible specific endpoints and criteria that will be used to evaluate its efficacy and safety against the mRNA vaccine comparator? Speaker 700:17:50And can you also elaborate on what enrollment for this study would look like such as where you might enroll patients from and are there any other challenges you might anticipate? Speaker 200:18:02Sure. I'll turn that over to James since he has the details on that. Speaker 600:18:08Sure. So as far as where we're actually executing the clinical trial, it's planned to be executed here in the United States. And in terms of enrollment, it would be healthy individuals and individuals at risk above the age of 18. It's important that we test this vaccine against the comparator mRNA vaccine in a population that's likely to do the most good. So we're moving along those lines. Speaker 600:18:38What was the second part of your question, ASEA? Speaker 700:18:43So it was about possible endpoints and criteria that you will be using for the study? Speaker 600:18:50Yes. So the endpoints are safety always, right? And we're very fortunate in that our platform across every article in our pipeline portfolio has been very well received, very safe and well tolerated. We'll also be looking at efficacy, both for symptomatic COVID-nineteen infection compared to the comparator vaccine. And we'll be looking at the immunological readouts and mucosal readouts of that vaccine. Speaker 700:19:23Okay. Thank you so much. That makes a lot of sense. Speaker 400:19:27Thank you. Operator00:19:31And our next question comes from Roger Song with Jefferies. Please state your question. Speaker 800:19:37Hey, good afternoon. This is Liang Chen on for Roger. Thank you for taking our questions. I guess from us, so understand that you have met with the FDA yet, but regarding the potential Phase 2 challenge study, So what would be some considerations around whether there would be such a study or no? And also I have a question about the potential immunology correlates. Speaker 800:20:08So could you remind us if you are still continuing on data analysis and are there any updates or plans on the immunogenicity correlates? Thank you. Speaker 200:20:24Sure. Yes. I'll turn it over to James shortly. My high level is, obviously, what we've stated in terms of our meeting with the FDA is we're still targeting middle of this year. And James can cover a bit more about that. Speaker 600:20:43Thanks, Steve. So as we mentioned, we'll be planning to we'll be meeting with the FDA in mid-twenty 24. And we'll review our clinical findings to date. That includes data on potential correlates of protection. We anticipate this meeting will assist us in determining the proper regulatory pathway and clinical next steps. Speaker 600:21:06And as I mentioned in my brief, some of these steps could include a Phase 2b dose confirmation study and if required, a G24 challenge study. But I'd like to get input from the agency. We'll determine the timing of any future norovirus studies after our discussions with the FDA. Speaker 800:21:31Got it. That makes sense. So, also regarding the Phase 1 lactating mothers data, I know the detailed data will be published in future. Would there be any data around measurements in the infants? Speaker 200:21:51James or Sean, either one of you want to take that? Speaker 600:21:55Sure. So the data we have to date, Leon, is some of the top line data and we continue to perform analyses. Some of those analyses will look at fecal, the amount of material in the infant species. But that's again down the road a bit. Speaker 800:22:22Got it. Thank you. That's all from us. Thanks again. Operator00:22:27Thank you. I would now like to turn the call back to Ed Berg for further questions. Speaker 100:22:35Okay. Thank you. Have additional questions that came in from investors. So I will start with our Phase 2b COVID study. And this is for James. Speaker 100:22:48Do you have enough manufacturing capacity to produce your COVID vaccine for the Phase 2b trial? Speaker 600:22:56Sure. Thanks for the question. Yes, beef have sufficient material that's already been produced. Speaker 100:23:05Thanks. The other question for you, James, on COVID the COVID trial is how does the fall COVID-nineteen booster season affect Vaxart's ability to procure mRNA vaccines for use in the control arm? Speaker 600:23:28Thanks, Ed. So this study is actually a comparator of homologous vaccines, 2 vaccines that are geared towards the same strain of the virus. We've already procured an XBV mRNA vaccine that is the comparative construct that we need for this trial. Speaker 100:23:52Thanks, James. On the 108 study, this is for Sean. In your recent press release announcing the Lactating Mothers study data, you mentioned antibody increase figures. How do these compare to the other published data? Speaker 900:24:12Yes, that's a great question. Well, there haven't been as many studies have done where the women postpartum have been vaccinated. Most studies in mothers have done in 3rd trimester, not after the infant is born. Moreover, there haven't really been that many actually been no doravirus vaccine trials in lactating mothers. Having said that, from the few studies that we will define on vaccination in postpartum mothers, we believe our results compare quite favorably. Speaker 900:24:41We're getting a similar response or better than what's been described. Speaker 100:24:49Thanks. Sean, back to the this is one for Sean, but back to COVID-nineteen and the Phase 2b trial. The question is what differentiates Vaxart's technology from the other next gen COVID vaccines that received contracts from BARDA? Speaker 900:25:07Well, first off, we're the only oral pill vaccine that's currently been contracted in the project next gen recipients. The benefit that we see is that it's just more convenient for administering our vaccine by injection or better than a nasal spray. The other advantage we have of course is that as James mentioned before is we actually have our own manufacturing facilities and they've been able to make vaccine quickly and it's competitive advantage for us because of that. Speaker 100:25:41Thanks. This one is also for Sean. And I think Steve, you might want to step in and make some comments. The question is how do you intend to educate the medical community and consumers on your COVID and norovirus oral vaccine benefits in order to rapidly drive adoption in the U. S, the U. Speaker 100:26:01K. And broadly, particularly given what has been learned about the shortcomings of existing vaccines and overall vaccine hesitancy. And of course, I will as the lawyer, I will state that we don't we're not going to be promoting our vaccines until they're approved. But there are other methods of communicating information. So Sean, with that, feel free to Speaker 800:26:28add. Sure. Speaker 900:26:29Well, we think our tablet vaccine will do well from the standpoint of overcoming vaccine hesitancy. In fact, we did do some previous polling data conducted in 2021 2022 and the latest suggests that 8 out of 10 recipients would prefer a pill to a shot or a nasal spray. So further, we have gone to various medical conferences and conferences and we have seen lots of positive feedback about our approach and we think the excitement is indicative of the understanding in the medical community that there may be some pent up demand for a new technology that's easier to use. Speaker 400:27:10Steve? Speaker 200:27:12Yes. Thanks, Sean. Sean is being modest. He gets invited to a lot of conferences to speak and I think any sort of scientific exchange like that is important. And I think as we continue releasing more data, having that opportunity to do so is important to us. Speaker 200:27:31As Ed mentioned, we're not FDA approved as of yet. So we'll stick to the regular medical scientific exchanges to make sure that what we have in our data is out there for everyone to absorb. Speaker 100:27:49Thank you, Steve. Another question directed to you. You mentioned in your prepared remarks having better execution. How do you think that can be accomplished? Speaker 200:28:02Yes. Thanks for the question. Well, I think first and foremost, we as a company want to make sure that we have our priorities set. And I'm delighted to see that we have, you've seen already or heard today, we've talked about making sure that we execute on the agreement with BARDA to prepare for this upcoming 10,000 subject trial. And it's already been demonstrated with the fact that as James mentioned, we have made great progress on the manufacturing front. Speaker 200:28:35We prepared and are preparing for the trial to the extent that you've heard more details about it. And so to me that is continued to execute. We want to balance that with making sure that we're very rigorous with everything that we're doing, but also understanding that we want to help the public out there. So anything we can do to balance that with good speed is also important. And that's certainly how I look at having better execution. Speaker 100:29:11Thanks. Last question for Steve. It's been nearly 2 months since you arrived as CEO. What have you learned in that time? Speaker 200:29:22Great. Thanks for that question. First and foremost, let me just say I'm delighted to be here. What I have found and learned is that this is what we have here at Vaxart is very promising science and one of the main reasons why I wanted to come here. And secondly, now that I've been here for 2 months, getting a chance to work side by side with the employees, our scientists, everybody, I can say that we are very passionate about our work and our mission. Speaker 200:29:52And if you combine the promising science with dedicated employees here at Backstart, we are very focused on wanting to advance our vaccine candidates forward and get it out there as soon as we can with the approvals that we need and with the trials that we need to execute and conduct. But we are very focused on execution and also delivering value to our stakeholders. Speaker 100:30:24Thanks, Steve. Thank you everyone for tuning in. I will turn it back over to our operator to close out the call. Operator00:30:35Thank you. This concludes conference. You may disconnect your lines at this time and have a wonderful day. We thank you for your participation today.Read morePowered by